A 74-Year-Old-Man with Metastatic Prostate Cancer - Episode 4

Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.